Latest Healthcare News

Page 16 of 197
HealthCo Healthcare and Wellness REIT (ASX: HCW) reported a $49.7 million FY26 statutory loss, suspended distributions and received an unmodified audit opinion that nevertheless highlighted a material uncertainty over its ability to continue as a going concern. The key unresolved issue is the transfer of 10 Healthscope hospitals to alternative operators.
Eva Park
Eva Park
25 Sept 2026
Ramsay Health Care delivered stronger FY26 earnings, a higher fully franked dividend and improved Funding Group leverage as it prepares to separate Ramsay Santé. The proposed demerger remains conditional, but the company has set a clear timetable for the next phase of its portfolio reshaping.
Ada Torres
Ada Torres
25 Sept 2026
GWA Group delivered its third consecutive year of volume growth in FY26, lifting revenue, normalised EBIT and its fully franked dividend despite weak housing and renovation conditions. The trade-off was a sharp decline in operating cash flow and higher net debt following inventory purchases and a $25 million share buyback.
Victor Sage
Victor Sage
25 Sept 2026
Sonic Healthcare delivered a strong FY2026, with underlying net profit up 17% to A$621 million and dividends rising to A$1.08 per share. The next test is whether US efficiencies, LADR synergies and organic growth can offset Swiss fee cuts, a delayed UK contract ramp-up and heavier investment demands.
Ada Torres
Ada Torres
24 Sept 2026
Nexsen has paused its StrepSure clinical programme after an interim review identified performance improvements needed before a US FDA submission, pushing the target timetable back by roughly one quarter. Its shares were then suspended pending an announcement about a potentially material contract for an additional device.
Ada Torres
Ada Torres
24 Sept 2026
Carlton Investments increased FY2026 profit and fully franked dividends, but its investment portfolio underperformed sharply as its largest holding, EVT, fell 22.6% in value. The company’s total portfolio return was negative 3.2%, compared with a 6.1% gain for the S&P/ASX 200 Accumulation Index.
Claire Turing
Claire Turing
24 Sept 2026
Vection Technologies has signed reciprocal five-year reseller agreements with Xerox, opening a potential Western European channel for its conversational AI, digital human, kiosk and XR technologies. The opportunity is strategically notable, but the agreements contain no minimum volumes, pricing or committed revenue.
Sophie Babbage
Sophie Babbage
24 Sept 2026
BCAL Diagnostics has begun introducing ClearNote Health’s Avantect Multi-Cancer blood test in Australia, starting with Sydney and Melbourne. The test reported 56.2% sensitivity and 98.4% specificity in a case-control validation study, but the company says a negative result does not rule out cancer.
Ada Torres
Ada Torres
23 Sept 2026
PainChek grew recurring revenue, implemented licences and customer sites in FY2026, but its $8.94 million loss and $9.24 million operating cash outflow prompted an explicit going-concern warning from its auditor. The company is now betting that US deployments and a sharper commercial focus can convert market access into cash-generating growth.
Victor Sage
Victor Sage
23 Sept 2026
Synertec has raised its FY27 revenue guidance by $8.0 million to $8.3 million, pointing to stronger contract conversion and visibility across its Engineering and Powerhouse businesses. The upgrade follows the $45.5 million ANSTO nuclear medicine manufacturing contract, but covers revenue only and not earnings or cash flow.
Victor Sage
Victor Sage
23 Sept 2026
Actinogen Medical has completed the final patient visit in its 247-participant XanaMIA Alzheimer’s disease trial, keeping topline results on track for November 2026. The milestone closes patient participation in the pivotal study, but provides no indication yet of whether Xanamem improved outcomes.
Ada Torres
Ada Torres
23 Sept 2026
Firebrick Pharma has received a $293,000 R&D Tax Incentive payment linked to $673,000 of eligible development spending on new Nasodine products. The non-dilutive cash arrives as the company broadens its product range and pursues approvals in additional markets.
Ada Torres
Ada Torres
23 Sept 2026

Browse the archive

Full archive